Vitamin E and platelet aggregation.

P C Huijgens; C A van den Berg; L M Imandt; M M Langenhuijsen

doi:10.1159/000207181

Home/Archive/PubMed

PubMed · 6785976

Vitamin E and platelet aggregation.

P C Huijgens·C A van den Berg·L M Imandt·M M Langenhuijsen

View original source ↗Export metadata ↓

Abstract

In healthy persons, a daily dose of 2,000 IU of vitamin E given for 10 days does not prolong the bleeding time and has no influence on collagen- and ADP-induced platelet aggregation nor on platelet prostaglandin synthesis. Therefore, even high doses of vitamin E have no place in platelet function suppressing therapy.

Explore related subjects

Administration, Oral Bleeding Time Blood Platelets Humans Male Malondialdehyde Platelet Aggregation Vitamin E Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

P C Huijgens, C A van den Berg, L M Imandt, M M Langenhuijsen. 1981. Vitamin E and platelet aggregation.. https://doi.org/10.1159/000207181

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Oral ganciclovir for cytomegalovirus retinitis.

Explore the source record for details and available documents.

Administration, Oral↗

PubMed1996

Oral ganciclovir for cytomegalovirus retinitis.

Explore the source record for details and available documents.

Administration, Oral↗

PubMed1996

A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence.

PURPOSE: We evaluated the efficacy and safety of yohimbine and isoxsuprine or pentoxifylline in the management of vasculogenic erectile dysfunction. MATERIALS AND METHODS: A total of 20 patients diagnosed with arterial insufficiency and cavernous venous leakage by pharmacological penile duplex scanning underwent nonhormonal oral therapy. A randomized crossover study was performed using 5.4 mg. yohimbine plus 10 mg. isoxsuprine or 400 mg. pentoxifylline 3 times daily. Response to therapy was assessed by a sexual questionnaire and repeat penile duplex ultrasonography. RESULTS: No patient in either phase of the study in either group had a complete response to the oral regimen(s) and there was no improvement in the pre-injection or post-injection cavernous arterial peak systolic flow velocities or resistance indexes. CONCLUSIONS: Our study suggests that these oral agents, although well tolerated, were not effective in the management of these patients with mixed vasculogenic erectile dysfunction.

Administration, Oral↗